Straits Times Index
3,240.58 +49.87 (+1.56%) Nikkei
26,739.03 +336.19 (+1.27%) Hang Seng
20,717.24 +596.56 (+2.96%) FTSE 100
7,389.98 +87.24 (+1.19%) BTC-USD
29,726.94 +349.19 (+1.19%) CMC Crypto 200
650.34 -23.03 (-3.42%)
Seres Therapeutics, Inc. (MCRB)
- Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome company, today announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections (rCDI) by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle. These data were shared in oral and poster presentations at t
- Business Wire
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
CAMBRIDGE, Mass., May 10, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present data from its ECOSPOR III trial of SER-109 at the Digestive Disease Week® (DDW) Annual Meeting, which is taking place May 21-24, 2022. SER-109 is an investigational oral microbiome therapeutic for the prevention of recurrent C. difficile infection (rCDI). With an oral and poster presentation, Seres will present data on how SER-109 restores the f
- Zacks
Seres Therapeutics (MCRB) Reports Q1 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.93% and 79.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
